Abstract：Guillain-Barré syndrome is a peripheral neuropathy mediated by autoimmune,it′s characterized by paralysis of limbs,disappearance of tendon reflex and separation of protein and cell in cerebrospinal fluid.Because of the result of respiratory paralysis,it is one of the most common acute and severe neurological diseases.The exact etiology of GBS is unknown,Campylobacter jejuni may be related to it,now that the molecular mimicry theory is one of the probably most important pathogenesis.Respiratory management is an important measure to improve the general condition and improve prognosis with respiratory muscle paralysis.In recent years,many scholars have explored and studied the traditional immunotherapy,and some new treatment methods are found at the same time.In this paper,the newest research progress of GBS in recent years are reviewed.
崔国静; 李 勤. 吉兰-巴雷综合征的研究进展[J]. 中国当代医药, 2018, 25(6): 25-27.
CUI Guo-jing; LI Qin. The research progress of Guillain-Barré syndrome. 中国当代医药, 2018, 25(6): 25-27.
El-Bayoumi MA，El-Refaey AM，Abdelkader AM，et al.Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome：a randomized study[J].Crit Care，2011，15（4）：R164.
[2]
Harms M.Inpatient management of Guillain-Barré syndrome[J].Neurohospitalist，2011，1（2）：78-84.
Islam Z，Jacobs BC，van Belkum A，et al.Axonal variant of Guillain-Barré syndrome associated with Campylobacter infection in Bangladesh[J].Neurology，2010，74（ 7）：581-587.
[4]
McCarthy N，Giesecke J.Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni[J].Am J Epidemiol，2001，153（6）：610-614.
[5]
Goodyear CS，0’Hanlon GM，Plomp JJ，et al.Monoclonal antibodies raised against Guillain-Barré syndrome associated Campylobacter jejuni lipopolysaceharides react with neuronal gangliosides and paralyze muscle-nerve preparations[J].J Clin Invest，1999，104（6）：697-708.
[6]
Nachamkin I，LIU J，Li M，et al.Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses a GDla-like epitope[J].Infect Immun，2002，70（9）：5299-5303.
[7]
Takabashi M，Koga M，Yokoyama K，et al.Epidemiology of Campylobacter jejuni isolated from patients with Guillain-Barré and fisher syndromes in Japan[J].J Clin Microbiol，2005，43（1）：335-339.
[8]
Godschalk PCR，Heikema AP，Gilbert M，et al.The crucial role of Campylobacter jejun genes in anti-ganglio-side antibody induction in Guillain-barré syndrome[J].J Clin Invest，2004，114（11）：1659-1665.
[10]
Cao-lormeau VM，Blake A，Mons S，et al.Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia：a case-control study[J].Lancet，2016，387（10027）：1531-1539.
[11]
Brasil P，Sequeira PC，Freitas AD，et al.Guillain-Barré syndrome associated with Zika virus infection[J].Lancet，2016，387（10026）：1482.
[16]
Condino-Neto A，Costa-Carvalho BT，Grumach AS，et al.Guidelines for the use of human immunoglobulin in therapy in patients with primary immunodeficiencies in Latin America[J].Allergol Immunopathol（Madr），2014，42（3）：245-260.
[17]
Szczepiorkowski ZM，Winters JL，Bandarenko N，et al.Guideline on the use of therapeutic apheresis in clinical practiceevidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis[J].J Clin Apher，2010，25（3）：83-177.
京公网安备 11010502046607号